StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) stock

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.57−1.93 (-4.34%)

Close on Nov 16, 2026Market cap $49.61BP/E 71.0Yield –

Teva Pharmaceutical Industries operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Teva Pharmaceutical Industries's operating cash flow for the twelve months ending Jun 30, 2026 was $1.90B, up 36.5% year over year. For fiscal 2025 it was $1.65B, up 32.2% from the year before. Over ten years it grew -11.4% a year on average. The highest annual figure on record is $5.54B in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.65B+32.2%
FY2024Dec 31, 2024$1.25B-8.8%
FY2023Dec 31, 2023$1.37B-14.0%
FY2022Dec 31, 2022$1.59B+99.2%
FY2021Dec 31, 2021$798.00M-34.4%
FY2020Dec 31, 2020$1.22B+62.6%
FY2019Dec 31, 2019$748.00M-69.4%
FY2018Dec 31, 2018$2.45B+9.9%
FY2017Dec 31, 2017$2.23B-42.8%
FY2016Dec 31, 2016$3.89B-29.8%
FY2015Dec 31, 2015$5.54B+8.1%
FY2014Dec 31, 2014$5.13B+58.4%
FY2013Dec 31, 2013$3.24B-29.2%
FY2012Dec 31, 2012$4.57B+10.6%
FY2011Dec 31, 2011$4.13B-0.0%
FY2010Dec 31, 2010$4.14B+22.6%
FY2009Dec 31, 2009$3.37B+4.4%
FY2008Dec 31, 2008$3.23B+78.2%
FY2007Dec 31, 2007$1.81B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$411.00M+81.1%
Q1 FY2026Mar 31, 2026-$40.00M–
Q4 FY2025Dec 31, 2025$1.16B+101.4%
Q3 FY2025Sep 30, 2025$369.00M-46.8%
Q2 FY2025Jun 30, 2025$227.00M+120.4%
Q1 FY2025Mar 31, 2025-$105.00M–
Q4 FY2024Dec 31, 2024$575.00M-51.4%
Q3 FY2024Sep 30, 2024$693.00M+13760.0%
Q2 FY2024Jun 30, 2024$103.00M-68.2%
Q1 FY2024Mar 31, 2024-$124.00M–
Q4 FY2023Dec 31, 2023$1.18B+21.7%
Q3 FY2023Sep 30, 2023$5.00M-99.1%
Q2 FY2023Jun 30, 2023$324.00M+163.4%
Q1 FY2023Mar 31, 2023-$145.00M–
Q4 FY2022Dec 31, 2022$973.00M+113.4%
Q3 FY2022Sep 30, 2022$543.00M+2.6%
Q2 FY2022Jun 30, 2022$123.00M-43.6%
Q1 FY2022Mar 31, 2022-$49.00M–
Q4 FY2021Dec 31, 2021$456.00M+37.8%
Q3 FY2021Sep 30, 2021$529.00M+72.3%
Q2 FY2021Jun 30, 2021$218.00M-20.1%
Q1 FY2021Mar 31, 2021-$405.00M-232.8%
Q4 FY2020Dec 31, 2020$331.00M-38.5%
Q3 FY2020Sep 30, 2020$307.00M-5.5%
Q2 FY2020Jun 30, 2020$273.00M–
Q1 FY2020Mar 31, 2020$305.00M+172.3%
Q4 FY2019Dec 31, 2019$538.00M+46.6%
Q3 FY2019Sep 30, 2019$325.00M-22.8%
Q2 FY2019Jun 30, 2019-$227.00M-240.1%
Q1 FY2019Mar 31, 2019$112.00M-92.5%
Q4 FY2018Dec 31, 2018$367.00M-57.3%
Q3 FY2018Sep 30, 2018$421.00M-47.0%
Q2 FY2018Jun 30, 2018$162.00M-62.8%
Q1 FY2018Mar 31, 2018$1.50B+1000.0%
Q4 FY2017Dec 31, 2017$859.00M+854.4%
Q3 FY2017Sep 30, 2017$795.00M-45.6%
Q2 FY2017Jun 30, 2017$435.00M–
Q1 FY2017Mar 31, 2017$136.00M–
Q4 FY2016Dec 31, 2016$90.00M–
Q3 FY2016Sep 30, 2016$1.46B–

More Teva Pharmaceutical Industries figures

See a number that looks wrong?